期刊文献+

两性霉素B效价测定方法的改进 被引量:3

Improvement of microbiological potency measurement of amphotericin B
下载PDF
导出
摘要 目的改进两性霉素B效价含量测定方法,提高方法的可靠性与可操作性。方法管碟法。新制培养基pH6.0~6.2;pH7.0磷酸盐缓冲液(含1%聚山梨醇);检定菌为啤酒酵母(ATCC9763);培养温度为(36±1)℃;培养时间为(20±2)hr:高、低剂量分别为10n5u/mL。结果抑菌圈大小符合规定,边缘清晰可以使用仪器进行测量:在1.09~10.90u/mL浓度范围内线性良好(回归方程:y=0.10763x+0.50076,r=0.99965);重现性与重复性好,日内精密度RSD=0.46%(n=6),日间精密度RSD=I.25%(n=12)。结论可以作为两性霉素B的常规质量控制方法。 Objective Improve the potency determination method of amphotericin B for the reliability and operability of the method. Methods The cylinder plate method with new medium(pH6.0±6.2) and pHT. 0 phosphate buffer (1% tween-80) was used. The test organism was Saccharomyces cerevisiae (ATCC9763); Incubation lasted 18-22 hours at the temperature(36±1)℃. The high and low doses were 10 and 5 amphotericin B units per mL respectively. Results The size of circular area (zone) of growth inhibition around the cylinder was moderate and the brim of ones was clear. The linearity was achieved over the range of 1.09-10.90u/mL (y=0.10763x+0.50076, r= 0.99965). The reproducibility and recovery were acceptable. The average relative standard deviation (RSD) of intra- day repeatability was 0.46% (n=6) and the average RSD The method has the potential to become the routine quality of inter-day repeatability was 1.25% (n=12). Conclusion control method for amphotericin B in pharmacopoeias.
作者 常艳 胡昌勤
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2013年第6期434-439,共6页 Chinese Journal of Antibiotics
基金 重大新药创制(No.2010ZX09401-403)
关键词 两性霉素B 效价测定 抗生素微生物检定法 不确定度 Amphotericin B Potency determination Microbiological assay of antibiotics Uncertainty
  • 相关文献

参考文献12

  • 1Gallis H A, Drew R H. Pickard W W. Amphotericin B:30 year of clinical experience[J]. Rer Infect Dis, 1990, 12: 308-329.
  • 2Li J, Zhu H Q, Li J Y, et al. Isolation, strucre elucidation and activity of an unknown impurity of amphotericin B[J]. J Antibiot, 2007, 60(4): 272-276.
  • 3Tran-Dinh S, Herve M, Lebourguais O, et al. Effects of amphotericin B on the glucose metabolism in Saccharomyces cerevisiae cells. Studies by 3C-, 1H-NMR and biochemical methods[J]. Eur JBiochem, 1991, 197 (1): 271-279.
  • 4Minodier P, Robert S, Noel G, et al. First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France[J]. Arch Pediatr, 2005, 12(7): 1102-1108.
  • 5Adedoyin A, Swenson C E, Bolcsak L, et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal injections[J]. Antimicrob Agents Chemother, 2000, 44: 2900-2902.
  • 6Martino R, Dupont B, Huckle H, et al. No signs of new toxicity when amphotericin B lipid complex (ABLC, Abelcet) and caspofungin are used in combination in the treatment of FUO[J]. Blood (Ash Ann Meet Abstr), 2004,104:5077.
  • 7The European Pharmacopoeia Commission. The European Pharmacopoeia 7th Ed[S]. Strasbourg: Council of Europe, 2011: 1391-1393.
  • 8The Ministry of Health, Labour and Welfare. The Japanese pharmacopoeia 16th Ed[S]. Tokyo: Society of Japanese Pharmacopoeia, 2011: 380-381.
  • 9The United States Pharmacopoeia Commission Inc. The United States United States Pharmacopeia 35th Ed [S]. Rockville, Md: the Pharmacopeia Convention, lnc, 2012: NF30,2012: 2206.
  • 10Chang Yan, Wang Y H, Hu C Q. Simultaneous determination of purity and potency of amphotericin B by HPLC[J]. JAntibiot, 2011, 64: 735-739.

二级参考文献9

共引文献7

同被引文献18

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部